In this article, we will discuss Anlotinib Tolerability (3). So, let’s get started.
The overall incidence of any AE with anlotinib was 100%, while 29% of patients reported grade 3/4 AEs, including hand-foot skin reaction (5%), hypertension (10%), triglyceride elevation (10%), and lipase elevation (5%). As the authors indicated, it is noteworthy that anlotinib appeared to cause less and milder diarrhea than did other oral anti-VEGFR TKIs.